| Bioactivity | VUT-MK142 is a potent new cardiomyogenic synthetic agent promoting the differentiation of pre-cardiac mesoderm into cardiomyocytes, which may be useful to differentiate stem cells into cardiomyocytes for cardiac repair[1]. | |||||||||
| Invitro | VUT-MK142 possesses promising cardiomyogenic effects on various cell types. VUT-MK142 shows a remarkable effect on both P19 and C2C12 cells. Compared to CgC, VUT-MK142-treatment leads to a markedly stronger up-regulation of the expression of ANF[1].VUT-MK142 (1 μM, 7 day treatment) significantly (p < 0.05) increases the luciferase signal by 3.1 ± 0.3 luciferase (n = 5)-fold in P19 cells[1]. | |||||||||
| Name | VUT-MK142 | |||||||||
| CAS | 1313491-22-3 | |||||||||
| Formula | C17H22N4O | |||||||||
| Molar Mass | 298.38 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Moumita Koley, et al. VUT-MK142 : a new cardiomyogenic small molecule promoting the differentiation of pre-cardiac mesoderm into cardiomyocytes. Medchemcomm. 2013 Aug 1;4(8):1189-1195. |
VUT-MK142
CAS: 1313491-22-3 F: C17H22N4O W: 298.38
VUT-MK142 is a potent new cardiomyogenic synthetic agent promoting the differentiation of pre-cardiac mesoderm into card
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.